Scientific Advisory Board

Barry Buckland, Ph.D.

Chairman, Scientific Adivsory Board, and Co-founder, Enumeral
Chief Executive Officer, BiologicB

Dr. Buckland has been a member of our Board of Directors since 2009. His career in the pharmaceutical industry includes leadership of Merck’s world class Bioprocess Research and Development Group which saw the market launch of major biological products, including Gardasil®, Rotateq®, and Zostavax®. Dr. Buckland has been the Chief Executive Officer of BiologicB, a consulting firm working with biotechnology and vaccine products, since 2009. He is the recipient of numerous awards, among them the Donald Medal, UK Institute of Chemical Engineering in 2002, Prix Galien award as a member of the team that received the Vaccine Award for Gardasil in 2007, the Marvin Johnson award by ACS for lifetime contribution to Biotechnology in 2008, and the PhRMA Discoverer of the Year for development of the Merck HPV vaccine (along with Eliav Barr and Kathrin Jansen) in 2009. Dr. Buckland has chaired multiple International Conferences related to bioprocess research and development and vaccine technology and is an author on over 70 papers. He has been a Visiting Professor at University College London since 1995. Dr. Buckland earned his Ph.D. in biochemical engineering at University College London.

Giulio Draetta, M.D., Ph.D.

University of Texas MD Anderson Cancer Center

Dr. Draetta serves a professor in the Department of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center. He is also the Director of the MD Anderson Institute for Applied Cancer Science. Prior to joining MD Anderson, Dr. Draetta was the Dana-Farber Presidential Scholar, chief research business development officer and deputy director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute. Dr. Draetta previously held appointments at Merck Research Laboratories and at Pharmacia. During his time in academia, Dr. Draetta has spearheaded fundamental research in the biology of the eukaryotic cell division cycle and of DNA damage induced checkpoints. His research led to the discovery of the first mammalian cyclin-dependent kinase and to the demonstration that cyclin-dependent kinases and cyclins physically interact and regulate multiple cell cycle transitions in eukaryotes.

Dr. Draetta also was co-founder and vice president of research for Mitotix, a biotechnology company, where he established programs in cancer, inflammation and infectious diseases that led to successful partnerships with several pharmaceutical companies. He led numerous drug discovery and development programs, targeting cyclin-dependent kinases and other mitotic kinases, developmental pathways, receptor tyrosine kinases, AKT and PDK1 kinases, epigenetics and tumor metabolism, which led to two drug approvals in recent years. 

Dr. Draetta earned his medical and post-graduate degrees from the University of Naples Medical School in Italy, where he also did post-graduate training. Dr. Draetta also served the Fogarty International Center Fellow at the National Cancer Institute of the National Institutes of Health, and as the Robertson Fellow at Cold Spring Harbor Laboratory. Dr. Draetta was a group leader at Cold Spring Harbor Laboratory, at the European Molecular Biology Laboratory (Heidelberg), and at the European Institute of Oncology (Milan).

Kai Wucherpfennig, M.D., Ph.D.

Dana-Farber Cancer Institute and Harvard Medical School

Dr. Wucherpfennig serves as Co-chair of the Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute, and also serves as Professor of Neurology at Harvard Medical School. At Dana-Farber, Dr. Wucherpfennig is principally involved in laboratory research that focuses on T cell immunology and the role of T cells in cancer immunology. 

Dr. Wucherpfennig’s lab aims to develop the next generation of cancer immunotherapies by in-depth mechanistic studies that identify the critical molecular switches controlling the ability of T cells to destroy cancers in highly immunosuppressive tumor microenvironments. Dr. Wucherpfennig’s lab recently reported a novel in vivo approach that enables discovery of negative regulators of T cell function in tumors. In addition, his lab has also developed novel approaches to investigate immune responses in patients responding to cancer immunotherapies. Dr. Wucherpfennig has received a number of honors and awards, including his election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation.

Dr. Wucherpfennig received his medical and post-graduate degrees from the University of Goettingen in Germany. He completed research fellowships at Brigham and Women's Hospital and at the Department of Molecular and Cellular Biology at Harvard University.